|제목||Celltrion Healtchare PR video|
In a hectic world, many people get lost in their busy lives, often overlooking the smaller but important things. They can lose sight of others, those in need of our help. The world could be a better place if people showed more warmth and offered a helping hand to those in need. At Celltrion, we appreciate and never lose sight of the people around us. We are committed to putting patients first and believe that everyone deserves access to the treatments they require Celltrion, is building on its leading position in the production of biologic medicines that are financially accessible and offer patients access to revolutionary treatments. Focusing on the potential of biosimilars, Celltrion has been at the forefront of biosimilar monoclonal antibody development. Celltrion Inc. focuses on developing high quality biosimilars and novel antibody therapeutics. Celltrion Healthcare conducts global marketing and sales and Celltrion Inc. product distribution Together, we provide biosimilar monoclonal antibodies and innovative biologic medications Our state-of-the-art mammalian cell culture facilities are designed to comply with FDA and EMA manufacturing standards. This enables us to offer the highest quality biologic medicines whilst retaining our leading position in the production of monoclonal antibodies A ‘Biosimilar’ medicine is highly similar to an already authorized ‘Biologic’ in terms of quality, safety and efficacy. As with biologics, a biosimilar is developed and approved via established regulatory pathways. Globally, Celltrion Healthcare has established a vast distribution network of partners and experts who have in-depth knowledge and experience in their local markets. Supported by more than a decade of research & investment, our products help give more people access to advanced biopharmaceutical therapies Celltrion has an extensive and promising pipeline of biologics to treat major disease areas including immunology, oncology and virology with additional monoclonal antibody candidates in development We are also developing novel biopharmaceuticals using the R&D capabilities and technologies that we have refined through years of research and production Remsima® leads the way as the world’s first biosimilar monoclonal antibody to be approved by the European Medicines Agency and the US Food and Drug Administration At Celltrion Healthcare, we are heading a new era in biologic therapy. We are committed to delivering affordable, high-quality, advanced therapeutics to patients and those who care for them And we never lose sight of what matters: our patients.